Israeli company Zebra Medical Vision has obtained the European CE-Mark for the use of its new artificial intelligence (AI) algorithm to detect various types of intracranial haemorrhages or brain bleeds.
The regulatory approval expands the firm’s Deep Learning Imaging Analytics platform under its All-In-One (AI1) business model.
This imaging platform also includes algorithms to automatically identify low bone mineral density, vertebral fractures, fatty liver, coronary artery calcium and emphysema, among other conditions.
According to statistics, around six million deaths per year occur due to brain bleed related conditions and therefore timely detection is considered important. The new algorithm is intended to address these challenges by accurately detecting such bleeds.
Zebra Medical Vision co-founder and CEO Elad Benjamin said: “We’re excited to announce our first acute care algorithm with the potential to help radiologists better manage their workload, and properly prioritise urgent cases over others.
“This helps take PACS & Worklist management systems to the next level in helping radiologists manage patient care, all in a transparent and globally affordable business model.”
With plans to introduce the new algorithm for point-of-care, the firm expects to equip physicians with better precision and minimal delay.
Furthermore, Zebra Medical is planning to launch additional high impact algorithms to deliver AI-based automated radiology assistance.
Intermountain Healthcare clinical and outreach services chief Dr Mike Phillips said: “The ability to alert radiologists and surgeons to the presence of brain bleeds is critical, and will bring significant benefits in patient care to healthcare organisations.”
In March last year, Intermountain Healthcare selected Zebra Medical Vision to deploy enterprise imaging analytics.